Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04476329
Title	Optimization for Regorafenib in HCC (ReDos HCC)
Acronym	ReDos HCC
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	SC Liver Research Consortium, LLC
Indications	hepatocellular carcinoma
Therapies	Regorafenib
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 9 of 9 entries

Facility	City	State	Zip	Country	Details
Albert Einstein Medical Center	Philadelphia	Pennsylvania	19141	United States	Details
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	United States	Details
Cancer and Hematology Centers of Western Michigan	Grand Rapids	Michigan	49503	United States	Details
Comprehensive Cancer Centers of Nevada	Henderson	Nevada	89014	United States	Details
Henry Ford Health Systems	Detroit	Michigan	48202	United States	Details
Saint Louis University	Saint Louis	Missouri	63104	United States	Details
Tulane University	New Orleans	Louisiana	70112	United States	Details
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	United States	Details
VA Long Beach Health System	Long Beach	California	90822	United States	Details

Showing 1 to 9 of 9 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field